Oumnia Bouaddi

Prof. Oumnia Bouaddi

Université Mohammed VI des Sciences de la Santé, Casablanca, Casablanca-Settat, Morocco
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2022 in Clinical Epidemiology and Global Health
Verified
Journal Article
Open access
OUOlivier Uwishema
Olivier Uwishema
EEEmmanuel Ebuka Elebesunu
Emmanuel Ebuka Elebesunu
OBOumnia Bouaddi
Oumnia Bouaddi
AKArushi Kapoor
Arushi Kapoor
SASamaa Akhtar
Samaa Akhtar
Helen OnyeakaHelen Onyeaka
Helen Onyeaka
Poliomyelitis is the leading infectious cause of acute flaccid paralysis among children under five years of age, caused by the Wild Poliovirus, with no medical cure other than prevention through vaccination. The advent of mass vaccination campaigns against polio disease worldwide has greatly decreased the number of global cases and limited the rate of transmission. However, the emergence of Vaccine-derived Poliovirus due to genetic reversions in the live attenuated oral polio vaccine has posed a significant impediment to global polio eradication efforts. Therefore, There is a need to modify the vaccination regimen by utilizing more doses of inactivated poliovirus vaccine or adopting the bivalent oral polio vaccine in order to eliminate the transmission of Vaccine-derived Poliovirus. In addition, collective efforts from governments, health policymakers, vaccination groups and health-related bodies are required to improve vaccine coverage and suppress the circulation of Vaccine-derived Poliovirus.

13 June 2023 in BMJ Global Health
Verified
Journal Article
Open access
PDF file
OBOumnia Bouaddi
Oumnia Bouaddi
SZSaad Zbiri
Saad Zbiri
Zakaria BelrhitiZakaria Belrhiti
Zakaria Belrhiti
Introduction Migrants’ access to sexual and reproductive health (SRH) services is constrained by several individual, organisational and structural barriers. To address these barriers, many interventions have been developed and implemented worldwide to facilitate the access and utilisation of SRH services for migrant populations. The aim of this scoping review was to identify the characteristics and scope of interventions, their underlying theory of change, reported outcomes and key enablers and challenges to improve access to SRH services for migrants. Methods A scoping review was conducted according to the Arksey and O’Malley (2005) guidelines. We searched three electronic databases (MEDLINE, Scopus and Google Scholar) and carried out additional searches using manual searching and citations tracking of empirical studies addressing interventions aimed at improving access and utilisation of SRH services for migrant populations published in Arabic, French or English between 4 September 1997 and 31 December 2022. Results We screened a total of 4267 papers, and 47 papers met our inclusion criteria. We identified different forms of interventions: comprehensive (multiple individual, organisational and structural components) and focused interventions addressing specific individual attributes (knowledge, attitude, perceptions and behaviours). Comprehensive interventions also address structural and organisational barriers (ie, the ability to pay). The results suggest that coconstruction of interventions enables the building of contextual sensitive educational contents and improved communication and self-empowerment as well as self-efficacy of migrant populations, and thus improved access to SRH. Conclusion More attention needs to be placed on participative approaches in developing interventions for migrants to improve access to SRH services.

29 February 2024 in Journal of Travel Medicine
Verified
Journal Article
Open access
ZCZeinab Cherri
Zeinab Cherri
KLKaren Lau
Karen Lau
LNLaura B Nellums
Laura B Nellums
JHJan Himmels
Jan Himmels
ADAnna Deal
Anna Deal
SHSally Hargreaves
Sally Hargreaves
Background: Ensuring vaccination coverage reaches established herd immunity thresholds (HITs) is the cornerstone of any vaccination programme. Diverse migrant populations in European countries have been associated with cases of vaccine-preventable diseases (VPDs) and outbreaks, yet it is not clear to what extent they are an under-immunized group. Methods: We did a systematic review and meta-analysis to synthesize peer-reviewed published primary research reporting data on the immune status of migrants in EU/EEA countries, the UK and Switzerland, calculating their pooled immunity coverage for measles, mumps, rubella and diphtheria using random-effects models. We searched on Web of Science, Embase, Global Health and MEDLINE (1 January 2000 to 10 June 2022), with no language restrictions. The protocol is registered with PROSPERO (CRD42018103666). Findings: Of 1103 abstracts screened, 62 met eligibility criteria, of which 39 were included in the meta-analysis. The meta-analysis included 75 089 migrants, predominantly from outside Europe. Pooled immunity coverage among migrant populations was well below the recommended HIT for diphtheria (n = 7, 57.4% [95% confidence interval (CI): 43.1–71.7%] I2 = 99% vs HIT 83–86%), measles (n = 21, 83.7% [95% CI: 79.2–88.2] I2 = 99% vs HIT 93–95%) and mumps (n = 8, 67.1% [95% CI: 50.6–83.6] I2 = 99% vs HIT 88–93%) and midway for rubella (n = 29, 85.6% [95% CI: 83.1–88.1%] I2 = 99% vs HIT 83–94%), with high heterogeneity across studies. Interpretation: Migrants in Europe are an under-immunized group for a range of important VPDs, with this study reinforcing the importance of engaging children, adolescents and adults in ‘catch-up’ vaccination initiatives on arrival for vaccines, doses and boosters they may have missed in their home countries. Co-designing strategies to strengthen catch-up vaccination across the life course in under-immunized groups is an important next step if we are to meet European and global targets for VPD elimination and control and ensure vaccine equity.

1 September 2023 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
Okesanya John OlalekanOkesanya John Olalekan
Okesanya John Olalekan
EMEmery Manirambona
Emery Manirambona
NONoah Olabode Olaleke
Noah Olabode Olaleke
HOHisham Alhassan Osumanu
Hisham Alhassan Osumanu
AFAyodeji Amos Faniyi
Ayodeji Amos Faniyi
DIDon Eliseo Lucero-Prisno III
Don Eliseo Lucero-Prisno III
The Marburg virus disease (MVD) is caused by a rare RNA virus that can result in severe hemorrhagic fever in humans and other primates. The disease was first discovered in 1967 in Marburg Frankfurt in Germany and since then, sporadic cases have been reported in southeastern Africa. The Egyptian fruit bat is considered a reservoir for the virus, which can be transmitted through direct contact with infected bat or monkey tissue, bodily fluids, or contaminated objects. The Marburg virus disease shares clinical features with the Ebola virus disease, and there are no widely accepted vaccines or antiviral medications to treat it. The article provides an overview of Marburg virus (MARV) outbreaks in Africa, including the most recent outbreaks in Guinea, Ghana, Equatorial Guinea, and Tanzania. The authors discuss the recent outbreaks and the implications of the spread of MARV to Africa’s healthcare systems. The authors also present key recommendations for both multicountry and global preparedness efforts in order to better prevent and respond to future MARV outbreaks and other viruses with an epidemic potential.

22 November 2024 in eClinicalMedicine
Verified
Journal Article
Open access
OBOumnia Bouaddi
Oumnia Bouaddi
FSFarah Seedat
Farah Seedat
HMHassan Edries Hasaan Mohammed
Hassan Edries Hasaan Mohammed
SEStella Evangelidou
Stella Evangelidou
ADAnna Deal
Anna Deal
SHSally Hargreaves
Sally Hargreaves
The Middle East and North African (MENA) region is a major global hotspot for migration with more than 40 million migrants, who may be an under-vaccinated group because of barriers to vaccination within countries of origin, transit, and destination. We systematically synthesised the evidence on coverage, acceptance, drivers of uptake, and policies pertaining to vaccination for children and adult migrants in the region, in order to explore tailored interventions for these groups. We searched six databases (including Medline, Embase) for peer-reviewed literature, and other websites (including WHO, IOM, ministries of health) for grey literature on coverage, acceptance, drivers of uptake and policies for any vaccination in migrants in the MENA region from between 2000 and 27 August 2024 in any language. We included studies reporting primary data on coverage, acceptance, and drivers of uptake, and any relevant articles on policies. We defined migrants as individuals who move away from their place of habitual residence, within or across international borders, temporarily or permanently. Studies without disaggregated migrant data were excluded. Primary outcomes were coverage (% individuals receiving ≥1 doses of any vaccine) and acceptance (% individuals accepting any vaccine). We separately synthesised data on children (<18 years) and adults (≥18). Estimates were pooled using a random-effects meta-analysis where possible or narratively synthesised, and drivers of uptake were synthesised using the WHO Behavioural and Social Drivers model. PROSPERO protocol: CRD42023401694. We identified 6088 database and 282 grey literature records and included 55 studies and 1,906,975 migrants across 15 countries (including mostly refugees in the Middle East and expatriates in Gulf Cooperation Council countries). COVID-19 vaccination was reportedly provided free of charge to migrants in all countries whereas childhood vaccinations were reportedly provided to migrant children in seven countries. However, for adolescents and adults, there were wide variations across countries, and we found no policies relating to catch-up vaccination. Coverage for childhood vaccination amongst migrants was reportedly low, with only 36.0% of 589 migrant children fully vaccinated according to national schedules (95% CI 35.0%–43.0%, I2 = 67%; data from migrants in Lebanon, Morocco, Sudan). Likewise, data on specific routine vaccines in children was generally low: measles containing vaccines (MCV): MCV dose 1 63.9%–66.9%; MCV dose 2 25.4%–85.6%; oral polio vaccine (OPV): OPV dose 3 65.1%–76.4%; diphtheria, tetanus and pertussis (DTP) containing vaccines: DTP dose 1 81.8%–86.7%; DTP dose 3 59.7%–76.6%). Drop-out rates across all routine vaccines for subsequent vaccine doses ranged from 12.4 to 38.5%, suggesting that migrants face a range of barriers to vaccine uptake beyond the first dose, that need to be better considered when designing interventions. For adults, we found eleven studies on coverage (including 9 on COVID-19) showing that COVID-19 vaccination coverage ranged 33.5–84.8% in migrants and 25.0–59.0% in host populations. Drivers of uptake of childhood vaccination in migrants included limited availability of vaccines and vaccination personnel, communication and administrative barriers, financial difficulties, lack of caregiver knowledge about services, and concerns expressed by caregivers around safety and benefits. For adults, drivers were mainly related to the COVID-19 vaccine and included concerns around safety, quality, side effects, and mistrust in vaccines and the systems that deliver them. Migrants have unique risk factors for under-immunisation in the MENA region and have low vaccination coverage despite some level of entitlement to services. Data on vaccination coverage, drivers of uptake and policies for migrants in the MENA region is limited to small-scale studies among accessible groups, mostly focusing on COVID-19 compared to routine childhood and adult vaccination. There is an urgent need to strengthen data collection to better understand coverage across different migrant groups, ages, and MENA countries, especially on adult and catch-up vaccinations for routine immunisations, and develop innovative co-designed strategies to address specific drivers of vaccine uptake among this group. La Caixa, LCF/PR/SP21/52930003.

11 April 2023 in BMC Women's Health
Verified
Journal Article
Open access
PDF file
LALaila Acharai
Laila Acharai
MKMohamed Khalis
Mohamed Khalis
OBOumnia Bouaddi
Oumnia Bouaddi
GKGhida Krisht
Ghida Krisht
SESanae Elomrani
Sanae Elomrani
BABouchra Assarag
Bouchra Assarag
Background: Over the past decade, Morocco has increasingly become the chosen destination for a growing number of migrants from neighbouring countries and especially from Sub-Saharan Africa. The aim of this study is to describe the sexual and reproductive health (SRH), as well as sexual and gender-based violence (SGBV) among female migrants in Morocco. Methods: This is a descriptive cross-sectional study conducted between July and December 2021. Female migrants were recruited from one university maternity hospital and two primary healthcare centres in Rabat. Data were collected using a structured face-to-face questionnaire, which included information about sociodemographic characteristics, SRH, history of SGBV and its impact, as well as the utilization of preventive and supportive SGBV services. Results: A total of 151 participants were included in this study. The majority of participants (60.9%) were aged 18 to 34 years old and 83.3% were single. Many participants (62.1%) did not use contraceptives. More than half (56%) of the participants who were pregnant at the time of the study were receiving pre-natal care. About 29.9% of interviewed participants reported experiencing female genital mutilation, and a significant majority (87.4%) experienced SGBV at least once during their lifetimes, while 76.2% experienced SGBV during migration. The most commonly reported form of violence was verbal abuse (75.8%). Among the victims of SGBV, a minority have visited a health facility (7%) or filed a complaint (9%) in the aftermath of violence. Conclusion: Overall, our findings showed low contraception coverage, moderate access to prenatal care, high prevalence of SGBV, and low utilization of preventive and supportive SGBV services among migrant women in Morocco. Further studies are needed to understand the contextual barriers to access, and utilization of SRH care and additional efforts should be undertaken to strengthen SGBV prevention and support systems.